Italia markets close in 7 hours 7 minutes

Bellerophon Therapeutics, Inc. (0HMP.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,4400+0,8780 (+56,21%)
Al 04:36PM BST. Mercato aperto.
Schermo intero
Chiusura precedente1,5620
Aperto1,0668
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,0160 - 1,0668
Intervallo di 52 settimane1,0160 - 1,0668
Volume300
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)-0,17
Rapporto PE (ttm)N/D
EPS (ttm)-1,8850
Prossima data utili03 ago 2022 - 08 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

    WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American Thoracis Society (ATS) 2022 International Conference, being held May 13-18, 2022, in San Francisco, CA. Presentation Details Session C103: It's not just about IPFPoster Title: A Phase 2 Trial of INOpulse in

  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

    WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on the continued advancement of our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstit

  • GlobeNewswire

    Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

    WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2021. “The development of our INOpulse® inhaled nitric oxide therapy platform remains our foremost priority, in order to address the significant unmet needs in fib